Startup · $29.9m raised · Biotech and pharma
Oral polymer drugs mimicking bariatric surgery for metabolic disease
Baltimore
Every investor coverage indicates participated in a round Glyscend, Inc. raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon Capital | Series A | - |
| Breakout Labs | Series A | - |
| Medical Research Commercialisation Fund (MRCF) | Series A | - |
| Santé Ventures | Series A | - |
Companies Glyscend, Inc. acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Glyscend, Inc.. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio